Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?

What Was Tested

Researchers studied NAD+ in this randomized controlled trial publication.

Both sevelamer and nicotinamide are prescribed for this purpose.

Why It Was Studied

Hyperphosphatemia control is a major issue in hemodialysis patients.

In the present secondary analysis of the NICOREN trial, the researchers investigated the impact of sevelamer and nicotinamide on uremic toxins, toxin precursors, and endotoxemia in chronic hemodialysis patients.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got NAD+ and who got the comparison, which limits bias.

Circulating uremic toxins (including phenylacetylglutamine, trimethylamine-N-oxide, p-cresyl sulfate, indoxyl sulfate, kynurenine, hippuric acid, indole-3-acetic acid, 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid, kynurenic acid, and p-cresyl glucuronide) and precursors were measured by ultra-performance liquid chromatography-tandem mass spectrometry, and urea, uric acid, phosphate, C-reactive protein, and intact parathyroid hormone by routine biochemistry methods.

Serum endotoxin (evaluated by lipopolysaccharide levels) and C-terminal fibroblast growth factor-23 levels were measured using enzyme-linked immunosorbent assay kits.

What Was Measured

In the present secondary analysis of the NICOREN trial, the researchers investigated the impact of sevelamer and nicotinamide on uremic toxins, toxin precursors, and endotoxemia in chronic hemodialysis patients.

PubMed files the paper under topics including Endotoxemia, Endotoxins, Fibroblast Growth Factor-23, Fibroblast Growth Factors, Hyperphosphatemia, Niacinamide and Phosphates.

What This Means in Plain Language

The paper is a randomized study of NAD+.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Drugs), a journal based in New Zealand.

More context: the NAD+ compound page, all human trials.